High-resolution computed tomography shows evidence of ILD.
The ACR/CHEST ILD Guidelines in Practice, a video
In collaboration with the American College of Chest Physicians, the ACR released two new comprehensive guidelines aimed at improving the screening, monitoring, and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs). Recently, Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, director of the Toronto Scleroderma Program and principal investigator for the guideline, and Elana J. Bernstein, MD, MSc, Florence Irving associate professor of medicine in the Division of Rheumatology at Columbia University, New York City, and co-first author, presented a webinar to talk about how the guidelines were developed and present some of the recommendations and their rationale: Watch the recording now!
What to vaccinate for and when to do so are challenges for rheumatologists and rheumatology professionals under normal circumstances. During the COVID-19 pandemic, even more questions are being raised, specifically regarding a possible vaccine for SARS-CoV-2. The ACR’s COVID-19 Practice and Advocacy Task Force is working on a guidance document to help ACR members address these pressing questions.
For some patients with systemic lupus erythematosus, regular repeated treatment with rituximab may prevent disease flare, according to a study from Cassia et al.
RA patients experience a higher rate of cardiovascular disease (CVD) events than controls. In a new study, Karpouzas et al. determined that current biologic disease-modifying anti-rheumatic drug use is associated with reduced long-term CVD risk, protective calcification of noncalcified lesions and a lower likelihood of new plaque formation in patients with early atherosclerosis.
The COVID-19 pandemic and response disrupted state legislative sessions and agendas in 2020, leaving many ACR priorities unfulfilled and highlighting the urgent need for vocal rheumatology leaders in Washington, D.C., and state capitols.
Bharat Kumar, MD, Advocacy 101 coordinator and Government Affairs Committee member, describes the virtual program designed to educate and empower rheumatology fellows in training, program directors and ARP members to advocate for issues that affect rheumatology practices and patients in advance of the Advocates for Arthritis that will take place virtually in September.
During the 2020 ACR State-of-the-Art Clinical Symposium, Zoltán Szekanecz, MD, PhD, addressed the risks of vascular disease and how to manage them in patients with rheumatic diseases.
For many months, the healthcare world has been significantly affected by the swift and perÂvasive effects of SARS-CoV-2, which causes COVID-19. The virus has severely affected the delivery of patient care by all providers, including those in hospitals and emergency care settings, who grappled with the response to massive influxes of COVID-19 patients, and those…
I should have paid more attention in medical school. If I had, I might have remembered enough about basic pathophysiology to know why everyone was suddenly pulling their patients off of lisinopril. For those of you who need a quick primer: When the pressure in the renal artery drops, the kidney secretes renin. Working together,…
The conversation with Stephen Hahn, MD, addressed challenges associated with hydroxychloroquine access during the COVID-19 public health emergency and handling patient concerns about potential cardiac side effects.
Editor’s note: Registration for ACR Convergence 2020 is now open. Less than a year after becoming editor in chief of The New England Journal of Medicine (NEJM), Eric Rubin, MD, PhD, found himself in the thick of the COVID-19 pandemic. SARS-CoV-2-related submissions flooded the journal office at an unprecedented pace, making an impact on the…